VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

  • End date
    Dec 23, 2024
  • participants needed
  • sponsor
    Vir Biotechnology, Inc.
Updated on 23 June 2021


This is a Phase 1a, first in human study in which healthy adult participants who are considered to be at low-risk for HIV infection and are seropositive for cytomegalovirus (CMV) will receive two doses of VIR-1111 or placebo. These participants will be assessed for safety, reactogenicity, tolerability and immunogenicity. There is an optional long-term follow-up study that would lengthen study participation for up to 3 years post-first dose.

Condition HIV I Infection
Treatment Placebo, VIR-1111
Clinical Study IdentifierNCT04725877
SponsorVir Biotechnology, Inc.
Last Modified on23 June 2021


Yes No Not Sure

Inclusion Criteria

Healthy males or healthy females of non-child-bearing potential between the ages of 18 to 50 at the time of screening
Positive CMV serostatus
Assessed by clinic staff as being low risk for HIV infection and committed to maintaining behavior consistent with low risk of HIV exposure through the last protocol visit
Willing to use condoms during intercourse through Week 36 or the end of the study
Willing to undergo HIV testing, risk reduction counseling, and receive HIV test results
Willing to comply with the protocol requirements regarding donation of blood, sperm or other tissues
In the opinion of the Investigator, generally in good health as determined from medical history and no clinically significant findings from physical examinations, vital signs, and laboratory values

Exclusion Criteria

Live in a home with children under the age of 6
Routine provision of child care to children under the age of 6
Have close contact with immunocompromised individuals
Have close contact with pregnant women or a partner planning to become pregnant during the course of the study
Health care provider who routinely comes into contact with immunosuppressed patients or pregnant women
Participant is immunocompromised
Participant has an autoimmune disorder
Positive HIV test at the time of study screening
Receipt of another investigational HIV or CMV vaccine candidate
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note